431 results about "Bronchial epithelium" patented technology

An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compounds for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases. Specifically, the present invention provides methods of testing for bronchial asthma or chronic obstructive pulmonary disease and methods of screening for compounds to treat the diseases based on the comparison of the expression levels of marker genes identified as described above.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).

The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-alpha, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence.

The invention belongs to the technical field of medicine, and particularly relates to an amorphous ambroxol hydrochloride compound and a preparation method thereof. The amorphous ambroxol hydrochloride compound has high purity and stability, does not have obvious moisture absorption and weight increase even under the condition of high humidity, ensures that relative substances do not grow, and has higher dissolution rate than crystalline ambroxol hydrochloride. The invention also relates to an application of the amorphous ambroxol hydrochloride compound in preparation of medicine for the treatment of acute and chronic pulmonary diseases with the symptom of ropy sputum and difficult expectoration, phlegm eliminating treatment of acute exacerbation of chronic bronchitis, asthmatic bronchitis and bronchial asthma, prophylactic treatment of lung complication after an operation, and treatment of infant respiratory distress syndrome (IRDS) of premature infants and neonates.

The present invention provides methods of identifying a genetic abnormality such as mutation in EGFR or KRAS or ALK which is associated with the management of lung cancer or diagnosing, prognosing or monitoring the treatment of pre-cancerous conditions of the lung, such as bronchial dysplasia or atypical alveolar hyperplasia (AAH), through the detection of at least one volatile organic compound indicative of these states.

An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof:

wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P¹ and P² are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH₂—, etc., Y is —CH₂—, —CO—, —SO₂—, etc., Z is —CO—, —SO₂—, etc., and R³ is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino,

is useful as a controlling agent of the function of CCR⁴ useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

The invention discloses an ambroxol hydrochloride oral solution and a preparation method thereof, and relates to a preparation method of western medicine, in particular to a medical production formula used for curing bronchitis and a preparation method thereof; the preparation method comprises the following steps: sucrose, preservatives and purified water are dissolved in a mixing mode so as to prepare simple syrup; the ambroxol hydrochloride, corrigents and preservatives are dissolved by the purified water so as to prepare ambroxol hydrochloride solution; the ambroxol hydrochloride solution and the simple syrup are stirred and mixed evenly, the corrigents and the preservatives are added successively and discontinuously and then the purified water is added to adjust the concentration. The invention has simple and reasonable process, and is easy to operate practically and the produced products have good stability; the products can used as common phlegm-eliminating drugs, has functions of increasing the liquid level of the respiratory tract, reducing mucus secretion, enhancing the secretion of pulmonary surfactant and the movement of cilium and preventing cough to a certain extent, and is applicable to acute respiratory disease and chronic respiratory disease, such as ropy sputum and difficult cough caused by acute bronchitis and chronic bronchitis, bronchial asthma and pulmonary tuberculosis, etc.

An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof:

, wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G¹, G², G³, G⁴ and G⁵ are CH or N, X is —NH—, —O—, —CH₂—, etc., Y is —CH₂—, —CO—, —SO₂—, etc., Z is a single bond, —CO—, —SO₂—, —NH—, —O—, —S—, —CONH—, —SO₂NH—, etc., R² is hydrogen, alkyl, alkoxy, halogen, etc., and R³ is carbocyclic group, heterocyclic group, alkyl, etc.,

is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and α4β1 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound.

A compound represented by the formula (I) etc. or a salt thereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component.

[wherein Y¹ represents a divalent aryl group etc., V¹ represents an aryl group etc., and R¹¹ to R¹⁴ represent H, OH or a halogen atom etc.]

The invention relates to an MTT (thiazolyl blue) cell toxicity test method of biological assessment of a total particle matter in cigarette smoke and belongs to the technical field of safety assessment of tobacco and cigarette smoke. The MTT cell toxicity test method is characterized by comprising the following steps of: inoculating and culturing immortalized human bronchial epithelial cells (BEAS-2B cells) and contaminating the total particle matter in the cigarette smoke; detecting the cell survival rate by adopting an MTT method; and analyzing and evaluating the cell toxicity of the total particle matter in the cigarette smoke according to a test result. Compared with the prior art, the MTT cell toxicity test method has the following characteristics that BEAS-2B cells are human cells and are target organ source cells acting on a human body by the smoke; a BEAS-2B cell system is used for carrying out cell toxicity assessment on the cigarette smoke and has the strong pertinence; in a testing process, steps of washing the cells for a plurality of times are reduced; and a formaldehyde fixing step does not need to be carried out so that a testing period is shortened, the operation is rapid and convenient, the sensitivity is high and the result is stable and reliable. Moreover, the MTT test method disclosed by the invention is further applicable to a smoke cell toxicity test of various cell systems and the commonality is strong.

The invention discloses a lung bronchial segmentation and calibration method. The method comprises the following steps of S1, extracting a lung airway tree region from image data; S2, setting an interested voxel region according to the lung airway tree region, and performing sharpening filtering processing on the interested voxel region; S3, classifying the voxel regions of interest through a deeplearning convolutional neural network according to the processed voxel regions of interest, removing leakage and tracking airway branches to obtain an optimized lung airway tree region; S4, extracting airway tree structure information from the optimized lung airway tree region, and obtaining a candidate name set of each airway and a weight of each candidate name through a lung airway name labeling model according to the lung airway tree region and the airway tree structure information; and S5, optimizing the names of each group of airway trees according to the weights, and implementing accurate and automatic labeling of the names of the airway trees to obtain airway name information.

The invention discloses a traditional Chinese medicine composition for treating cough and asthma diseases, a preparation method and a quality control method thereof. The composition is made from the bulk drugs blackberrylily rhizome, platycodon root, epimedium, hawthorn fruit (crude), peppergrass, houttuynia, astragalus root, Chinese ephedra (roasted), earthworm, Chinese yam rhizome, common anemarrhena rhizome, gecko and the like, high performance liquid chromatography is adopted in the quality control method to assay the epimedium, and thin layer chromatography is employed to quanlitatively identify the blackberrylily rhizome, the platycodon root, the epimedium, the astragalus root, the Chinese ephedra (roasted) and the earthworm. The composition has outstanding curative effect and the functions of nourishing qi and kidney, removing heat from the lung and dissolving phlegm, and relieving cough and asthma. The composition has very good curative effect on the cough and asthma caused by the qi deficiency of lung and kidney as well as the phlegm-heat stagnating in lung, acute bronchitis, chronic bronchitis and bronchial asthma with the syndromes.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

The invention belongs to the fields of cell biology and tumor tissue engineering materials and provides a three-dimensional tumor model decellularization porous scaffold, a construction method and application thereof. The whole pig lung scaffold is prefrozen, a uniform part without obvious bronchi is selected and sliced, purified water and PBS are added for cleaning until no blood streak is formed, removing cells with sodium dodecyl sulfate and TritonX-100, and freezing, drying and chemical crosslinking methods are adopted, so that a crosslinked decellularization pig lung three-dimensional tumor model scaffold is obtained. The three-dimensional tumor model decellularization porous scaffold provided by the invention has the advantages that decellularization matrix sourced from pig lung tissues is taken as a scaffold material for constructing a tumor model, on the basis of effectively removing cell components, a pulmonary alveolus-bronchus structural vein network is reserved as soon as possible, a natural extracellular matrix microenvironment can be simulated, and cell adhesion, growth and proliferation are facilitated. The in vitro constructed three-dimensional tumor model after cells are inoculated has a tissue structure closer to an in vivo tissue and is applicable to screening study of anticancer drugs.

Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.

The invention discloses Chinese herbal medicine decoction for curing bronchial asthma and a preparation method of the Chinese herbal medicine decoction. The Chinese herbal medicine decoction comprises, by weight, 9-11 parts of sophora japonica leaves, 7-9 parts of cortex lycii radicis, 3-5 parts of amethyst, 1-3 parts of cortex albiziae, 10-12 parts of cordyceps sinensis, 10-20 parts of sugarcane tops, 6-8 parts of human placenta, 8-10 parts of radix stemonae, 5-7 parts of ginseng, 2-4 parts of burdock, 9-11 parts of pomegranate blossom, 10-12 parts of beewax, 4-6 parts of stiff silkworm, 8-10 parts of cacumen biotae, 4-6 parts of fructus psoraleae, 10-15 parts of luffa stems, 3-5 parts of radix ilicis asprellae, 9-11 parts of shaddock peels and 10-12 parts of wild buckwheat. The Chinese herbal medicine decoction for curing bronchial asthma has effects of qi tonifying, lung cleaning, phlegm eliminating, spleen tonifying and qi absorption and is good in curative effect on the bronchitis, short in curing course, non-toxic and free of side effects.

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.

The invention discloses a human normal bronchial epithelial cell and preliminary isolated culture and subculture methods and purposes of the human normal bronchial epithelial cell. The cell is named as the human normal bronchial epithelial cell HNBEC/HL-001, the preservation number of the cell is CCTCCNO: C201311. The preliminary isolated culture method includes the steps that fat in a para-carcinoma tissue sample excised from a patient with lung cancer through an operation is removed, dispase and DNasel are added to the fat for action after the fat is digested, the cell is collected through filtering and centrifugal operations, and the cell is suspended again with an HL culture medium for inoculated culture. The subculture method includes the steps that when the cell proliferates to 70-90% abundance, pancreatin-EDTA is used for digestion, and then DMEM is used for neutralization; the cell is collected through a centrifugal operation, and the cell is suspended again with an HL culture medium for inoculated culture. The human normal bronchial epithelial cell can be used for physiological research of human normal cells, drug toxicity research and detection of external normal cells, and research on pathogenesis of bronchia and lung diseases including bronchogenic carcinoma.

The invention discloses a Bambuterol Hydrochloride oral disintegration tablet, wherein the principal drug employs Bambuterol Hydrochloride, the auxiliary materials include lactose, mannitol, crystalline cellulose, low replacement methylcellulose propylene glycol ether, cross bonding polyvinyl pyrrolidon, sodium hydrogen carbonate, citric acid, Aspartame, perfume compound, and magnesium stearate. The tablet has good treatment action for bronchial asthma, chronic bronchitis and pulmonary emphysema.

The invention discloses a medicine for treating allergic rhinitis and bronchial asthma and a preparation method thereof. The medicine is prepared by decocting aconite and liquorice according to a certain weight ratio, filtering the decoction, concentrating the filtrate, drying the concentrate, grinding the dried concentrate and adding medicinal adjuvants. The medicine is used for treating allergic rhinitis and bronchial asthma, is small in dose and less in medicinal flavor, has high efficacy and safety, low recurrence rate and good long-term efficacy, is low in cost and has good patient compliance.